Urinary biomarker and treatment mechanism of Rhizoma Alismatis on hyperlipidemia. (13th October 2016)

• Record Type: Journal Article
• Authors: Miao, Hua; Zhang, Li; Chen, Dan‐Qian; Chen, Hua; Zhao, Ying‐Yong; Ma, Shuang‐Cheng
• Is Part Of: Biomedical chromatography. Volume 31:Number 4(2017:Apr.)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2016-10-13
• Subjects: biomarker -- hyperlipidemia -- mass spectrometry -- Rhizoma alismatis -- ultra performance liquid chromatography -- urinary metabolomics; Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.3829
• Languages: English
• ISSNs: 0269-3879

Abstract

Abstract: Rhizoma Alismatis (RA), a diuretic in Asia and Europe, was found to possess anti‐hyperlipidemic activity. Since the biomarkers and mechanisms of RA in the treatment of hyperlipidemia are inadequate, ultra‐performance liquid chromatography coupled with quadrupole time‐of‐flight synapt high‐definition mass spectrometry and multivariate data analysis were employed to investigate the urinary metabolomics of RA on hyperlipidemic rats induced by high‐fat diet. The metabolic profile of RA‐treated hyperlipidemic group located between control and diet‐induced hyperlipidemic groups. Nineteen metabolites with significant fluctuations were identified as potential biomarkers related to the hyperlipidemia and anti‐hyperlipidemia of RA using partial least‐squares‐discriminate analysis, heatmap analysis and correlation coefficient analysis. The fluctuations of these biomarkers represented disturbances in amino acid metabolism, purine metabolism, pyrimidine metabolism and energy metabolism. After RA treatment, these perturbed metabolites were restored to normal or nearly normal levels. RA can alleviate high‐fat diet‐induced dysfunctions in these metabolic pathways.